Tohoku Univ. Technology：A novel therapeutic target Vasohibin-2: T18-447_T12-072
For the treatment of refractory cancers including pancreatic cancer
Vasohibin-2 (referred to as VASH2) knockdown significantly reduced metastasis of pancreatic cancer cells (Fig. 1) and prolonged survival period after orthotopic transplantation (Fig.2). The mechanisms of action are; (1)VASH2 knockdown reduces cancer cell invasion through suppressing of tubulin carboxypeptidase activity within the cell. (2) VASH2 secreted by cancer cells stimulates tumor angiogenesis, so when VASH2 was knocked down, tumor angiogenesis was prevented. (3) VASH2 regulates the production of inflammatory chemokines and cytokines in cancer cells, which in turn, accelerates the recruitment of MDSC and TAM and prevents the infiltration of cytotoxic T lymphocytes. The inhibition of VASH2 eliminates immune suppression in pancreatic cancer.
Inquire About This Product
basic information
For details, please contact us or refer to the PDF.
Price range
Delivery Time
Applications/Examples of results
For details, please contact us or refer to the PDF.
catalog（1）
Download All Catalogs
Company information
The revenue generated from technology transfer is reinvested as new research funding for universities and researchers, and is utilized to create further research outcomes. To ensure the smooth operation of this cycle, known as the "Intellectual Creation Cycle," we will vigorously promote technology transfer. The types of seeds we handle include patents, know-how, databases, and programs. We have established a collaborative framework by signing basic technology transfer agreements with the following universities (as of June 1, 2025): Tohoku University, Hirosaki University, Iwate University, Akita University, Fukushima University, Yamagata University, Tohoku Gakuin University, Iwate Medical University, Fukushima Medical University, Aizu University, Miyagi University, Hokkaido University, Muroran Institute of Technology, and Showa Medical University.
![[Research Material] Global Market for Esophageal Cancer Treatment Drugs](https://image.mono.ipros.com/public/product/image/9ce/2001460549/IPROS53369195814739762495.jpeg?w=280&h=280)
![[Research Material] Global Market for Muscle-Invasive Bladder Cancer Treatment](https://image.mono.ipros.com/public/product/image/f6c/2001472199/IPROS60138844813976939877.jpeg?w=280&h=280)
![[Research Material] Global Market for Treatment of Castration-Resistant Prostate Cancer](https://image.mono.ipros.com/public/product/image/5d5/2001470573/IPROS64934257799195914749.jpeg?w=280&h=280)
![[Research Material] Global Market for Bladder Cancer Treatment Drugs](https://image.mono.ipros.com/public/product/image/3aa/2001460626/IPROS40391824380644179480.jpeg?w=280&h=280)
![[Research Material] Global Market for Pancreatic and Bile Duct Cancer Treatments](https://image.mono.ipros.com/public/product/image/ed8/2001472100/IPROS43712803336624912264.jpeg?w=280&h=280)
![[Leveling Correction] Leveling correction of concrete floors "Teratec Method"](https://image.mono.ipros.com/public/product/image/d08/1267539002/IPROS70063422645318547243.jpeg?w=280&h=280)
